AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11974895
Drug: Medium-flow inhalation
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-flow inhalation of fluticasone dipropionate (DFP) (70 L/min)
Trial: 7772974
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (nebulized 4% lidocaine, 20 ml via oropharynx + transtracheal injection of 4% lidocaine, 3 ml)
Trial: 7772974
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve block (bilateral glossopharyngeal and superior laryngeal nerve blocks with 2% lidocaine, 0.5‐2 ml per injection site + transtracheal injection of 4% lidocaine, 3 ml)
Trial: 2182430
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in second or later remission
Trial: 219267
Drug: Thymosin fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin fraction V, 20 mg/sq m, twice weekly during the initial six weeks of chemotherapy
Trial: 219267
Drug: No thymosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thymosin treatment during the initial six weeks of chemotherapy
Trial: 30339627
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) at a dosage of 1000 mg/m every 2 weeks for 6 months
Trial: 30339627
Drug: S-1 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 at a dosage of 80 mg/m/d for 28 days every 6 weeks for 6 months
Trial: 23202265
Drug: Conditional cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditional cancer treatment subsidy
Trial: 22510537
Drug: Classification-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classification-based physical therapy
Trial: 12838091
Drug: Guideline-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based therapy
Trial: 24385026
Drug: Subcutaneous passive
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous passive drainage
Trial: 22248352
Drug: Budesonide/formoterol (200/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (200/6 µg, two inhalations bd)
Trial: 16024853
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide 2 mg
Trial: 16024853
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide 5 mg
Trial: 16024853
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide 13 mg
Trial: 12465720
Drug: Balloon treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon treatment for 13 weeks followed by balloon for 52 weeks
Trial: 12465720
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment for 13 weeks followed by balloon for 52 weeks
Trial: 12465720
Drug: Balloon treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon treatment for 52 weeks
Trial: 10591384
Drug: 0.9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg of rt-PA
Trial: 1655262
Drug: Lisinopril, Enalapril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril, Enalapril, Captopril
Trial: 23085185
Drug: Imagining a
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imagining a vulnerable individual (e.g., elderly man)
Trial: 20027350
Drug: Anaferon (pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaferon (pediatric formulation)
Trial: 11586013
Drug: Vitamin B(12)
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B(12) cream containing avocado oil
Trial: 28539168
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (ONS) in the form of two bottles a day of β‐hydroxy‐β‐methylbutyrate (HMB)
Trial: 29684990
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch (HES) infusion
Trial: 19358990
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg/kg
Trial: 10718795
Drug: Metoclopramide 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.2 mg/kg
Trial: 7800186
Drug: Diazepam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.1 mg/kg)
Trial: 16896962
Drug: Midazolam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.03 mg/kg)
Trial: 3287999
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation with intramuscular papaveretum
Trial: 3287999
Drug: Intramuscular papaveretum
RxNorm normalized name: papaveretum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular papaveretum alone
Trial: 29135664
Drug: Step 1
RxNorm normalized name: Nicotine Patch Step 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 1 (acetaminophen)
Trial: 22658588
Drug: C(1h) -
RxNorm normalized name: 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C(1h) - 6 mg kg(‐1) caffeine consumed 1 hour prior to exercise
Trial: 16685123
Drug: Rigorous glycaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigorous glycaemic control (RC) with i.v. insulin and intravenous crystalloid
Trial: 10834523
Drug: Indomethacin treatment
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin treatment
Trial: 8292466
Drug: Amlodipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (mean final dose 6.8 mg/day)
Trial: 29408986
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks)
Trial: 16390567
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 50 mg kg(‐1) bolus + 10 mg kg(‐1) h(‐1) continuous infusion (Group III, n = 20)
Trial: 14618196
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion (0.5 to 2 ng/kg/min over 6 hours)
Trial: 10831007
Drug: MDI (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI (1.0 mg inhaled flunisolide)
Trial: 10831007
Drug: MDI-S (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI-S (1.0 mg inhaled flunisolide with a spacer device)
Trial: 10831007
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration (1.0 mg of flunisolide with 240 mL of water)
Trial: 10831007
Drug: Intravenous (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (1.0 mg flunisolide by IV push)
Trial: 1425884
Drug: Nicardipine 20
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20 mg (acute treatment)
Trial: 1425884
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with Nicardipine SR
Trial: 31354158
Drug: Rivaroxaban (low-dose)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban (low-dose)
Trial: 29590422
Drug: Non-pharmacologic approaches
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacologic approaches for pain management (e.g., tai chi)
Trial: 20301996
Drug: Both continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both continuous and intermittent infusion of vancomycin
Trial: 14691416
Drug: Decision to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision to seek care to thrombolytic therapy (EMS)
Trial: 3036020
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 4 mg
Trial: 8393028
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 8 mg
Trial: 28937021
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg plus amoxicillin 750 mg (4 times/day for 14 days)
Trial: 28937021
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg plus amoxicillin 750 mg (4 times/day for 14 days)
Trial: 28937021
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple regimen (rabeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, clarithromycin 500 mg, 2 times/day for 14 days)
Trial: 23770332
Drug: Intradermal fractional-dose
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal fractional-dose IPV (ID-JI-0.1)
Trial: 23770332
Drug: Full-dose intramuscular
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose intramuscular needle (IM-NS-0.5)
Trial: 23770332
Drug: Full-dose intramuscular
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose intramuscular jet injector (IM-JI-0.5)
Trial: 23770332
Drug: Fractional-dose intramuscular
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional-dose intramuscular needle (IM-NS-0.1)
Trial: 23770332
Drug: Intradermal jet
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal jet injector (ID-JI-0.1)
Trial: 8927880
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg retarded nifedipine + 25 mg atenolol
Trial: 8927880
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg retarded nifedipine + 50 mg atenolol
Trial: 23826914
Drug: Polaprezinc (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polaprezinc (150 mg/day for 4 weeks)
Trial: 23826914
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no polaprezinc treatment)
Trial: 21739372
Drug: Emodepside/toltrazuril suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emodepside/toltrazuril suspension (at least 0.45 mg emodepside plus 9 mg toltrazuril per kg body weight)
Trial: 31164288
Drug: Community-based pulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based pulmonary rehabilitation (PR) for 3 weeks plus standard medication
Trial: 19785937
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication
Trial: 25512417
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg of eflornithine every 6 h for 14 days
Trial: 21732833
Drug: Rifapentine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine (900 mg) plus isoniazid (900 mg) weekly for 12 weeks
Trial: 21732833
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg) plus isoniazid (900 mg) twice weekly for 12 weeks
Trial: 21732833
Drug: Isoniazid (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (300 mg) daily for up to 6 years (continuous isoniazid)
Trial: 21732833
Drug: Isoniazid (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (300 mg) daily for 6 months (control group)
Trial: 9266231
Drug: Alfuzosin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 2.5 mg t.i.d. for 4 weeks
Trial: 9382121
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg alendronate
Trial: 8336198
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg alendronate
Trial: 8336198
Drug: >= 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >= 5 mg alendronate
Trial: 22074059
Drug: Cabergoline (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (0.25 mg twice weekly for 4 weeks followed by 0.5 mg twice weekly for the next 12 weeks)
Trial: 19649245
Drug: Rabies vaccine
RxNorm normalized name: RABIES VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabies vaccine (Rabipur; Chiron Behring GmbH)
Trial: 15599319
Drug: Everolimus 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 1.5 mg/day
Trial: 1930075
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (3.3 mg/kg body weight)
Trial: 6349363
Drug: Nitrofurantoin suppressive
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin suppressive therapy
Trial: 26374140
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with antioxidant nutrients (vitamin C 120 mg, β-carotene 6 mg, vitamin E 30 mg, selenium 100 µg, zinc 20 mg)
Trial: 23256821
Drug: Fluid ingestion
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid ingestion (FL) - 5 ml kg(‐1) before and 2 ml kg(‐1) every 15 min
Trial: 3903788
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 20 mg penbutolol plus 3 mg piretanide
Trial: 30922609
Drug: 7-session modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-session modified mindfulness-based cognitive therapy over 10 weeks
Trial: 25211921
Drug: Phytodrug prolit
RxNorm normalized name: Prolia
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phytodrug prolit super septo 2 capsules 2 times a day for 4 weeks
Trial: 15681169
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid (AA) administration up to four times within 12 hours based on initial AA concentration (4x500 mg AA for <34.1 micromol/l; 2x500 mg AA for < or =56.8 micromol/l; 1x500 mg AA for < or =68.2 micromol/l)
Trial: 11413075
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg per day for 4 weeks
Trial: 3142454
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups exposed to 4500 m altitude after treatment.
Trial: 12830444
Drug: Short daily
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short daily HD
Trial: 10877245
Drug: 10% (w/w)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% (w/w) glycolic acid scalp lotion
Trial: 8704119
Drug: Coconut oil
RxNorm normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut oil (63% C8:0 and 36% C10:0) at 6 g/day for 3 months (Control)
Trial: 6832206
Drug: Plain uncoated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain uncoated tablet (400 mg)
Trial: 6832206
Drug: Sustained-release tablet
RxNorm normalized name: Oratuss 12 Sustained-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tablet formulation 2 (400 mg)
Trial: 2245667
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline
Trial: 23400973
Drug: Capsaicin (Myolaxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (Myolaxin ointment)
Trial: 23400973
Drug: Control (plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (plain lubricant cream)
Trial: 20153216
Drug: Subcutaneous LMWH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous LMWH 40 mg once per day
Trial: 20153216
Drug: Subcutaneous LMWH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous LMWH 40 mg twice per day
Trial: 15717259
Drug: Immunoadjuvant prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunoadjuvant prednisolone therapy
Trial: 10673992
Drug: Relaxation training
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation training with guided imagery and L-arginine
Trial: 28209505
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BTX) injection
Trial: 20236700
Drug: LCZ696 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 100 mg
Trial: 20236700
Drug: LCZ696 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 400 mg
Trial: 24446062
Drug: LCZ696 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 (all doses)
Trial: 18498914
Drug: Cefteram pivoxil
RxNorm normalized name: cefteram pivoxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefteram pivoxil powder suspension (100 mg)
Trial: 12645861
Drug: Flt3 ligand
RxNorm normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flt3 ligand (20 microg/kg per day) administered subcutaneously daily for 14 days on a 28‐day cycle, monthly for four months
Trial: 12645861
Drug: Flt3 ligand
RxNorm normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flt3 ligand with the E75 peptide vaccine administered on day 7 of each flt3 ligand cycle
Trial: 12645861
Drug: Flt3 ligand
RxNorm normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flt3 ligand with the E75 peptide vaccine administered on day 14 of each flt3 ligand cycle
Trial: 10573704
Drug: Tazocillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazocillin (4 g piperacillin and 0.5 g tazobactam)
Trial: 21617138
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day n-3 PUFA
Trial: 19331721
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg) once daily for 12 weeks
Trial: 26535146
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 12 weeks
Trial: 8892713
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE), 0.625 mg/d
Trial: 14761878
Drug: HIGH-CHO (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH-CHO (10 g/kg body mass CHO)
Trial: 14761878
Drug: LOW-CHO (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW-CHO (0.7 g/kg body mass CHO)
Trial: 9389286
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide aerosol spray (110 microg in each nostril once daily)
Trial: 9389286
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous solution spray (100 microg in each nostril once daily)
Trial: 28334510
Drug: Testosterone cream
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cream (12.5 mg)
Trial: 28334510
Drug: Testosterone cream
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cream (25 mg)
Trial: 28334510
Drug: Testosterone cream
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cream (50 mg)
Trial: 28334510
Drug: Testosterone cream
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cream (all doses)
Trial: 22151296
Drug: NVA237 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 50 μg once daily
Trial: 18180343
Drug: Dihydroartemisinin-piperaquine (three-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (three-dose regimen)
Trial: 3739595
Drug: Glycopyrrolate (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (dosage ratio 2:1)
Trial: 6338689
Drug: Digoxin 0.25
RxNorm normalized name: digoxin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.25 mg
Trial: 10967698
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg